

# Provider Update

## Quarterly Pharmacy Formulary Change Notice

**Summary of change:** The formulary changes listed in the table below were reviewed and approved at our March 21, 2013, Pharmacy and Therapeutics Committee meeting.

✦ **What this means to you:** Effective June 1, 2013, the changes outlined below apply to all Amerigroup† patients.

### What is the impact of this change?

Effective for All Patients June 1, 2013			
Therapeutic Class	Drug	Revised Status	Potential Alternatives
Anticoagulants	Pradaxa	Adding to formulary with PA (Prior Authorization) and QL (Quantity Limits)	N/A
Anticoagulants	Xarelto	Adding to formulary with PA and QL	N/A
Vasodilating Agents	Letairis	Adding to formulary with PA and QL	N/A

### What action do I need to take?

Please work with your Amerigroup patients to transition to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific patients, you must obtain prior authorization to continue coverage beyond the applicable effective dates.

### What if I need assistance?

We recognize the unique aspects of patients' cases. If for medical reasons your Amerigroup patient cannot be converted to a formulary alternative, call our Provider Services team at 1-800-454-3730 and follow the voice prompts for pharmacy prior authorization. You can find the preferred drug list on this site.

If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730.

†In Louisiana, Amerigroup Louisiana, Inc. In New Mexico, Amerigroup Community Care of New Mexico, Inc. In Washington, Amerigroup Washington.

PEC-ALL-0902-13  
Issued April 2013  
By Amerigroup Pharmacy Dept.

